Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009

By Z. Younossi, M. Otgonsuren, L. Henry, C. Venkatesan, Alita Mishra, Madeline Erario, S. Hunt. Hepatology, 2015

734 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/a4ad63d3d47e6f5fdd934cc97421b5e476240ef1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. A. Sanyal
4. K. Cusi
5. R. Loomba
6. E. Brunt
7. J. Lavine
8. N. Chalasani

In Hepatology

1. Z. Younossi
2. M. Rinella
3. R. Loomba
4. K. Cusi
5. A. Sanyal
6. E. Brunt
7. H. B. EL‐SERAG
8. F. Tacke

Citations in the corpus

• Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease (2017, background): “8% reported in the literature for 2004-2009 (1).”
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, background): “Given the growing epidemic of obesity, the incidence of NAFLD-related HCC has been shown to increase at a 9% annual rate (61).”
• Non-alcoholic fatty liver disease - A global public health perspective. (2019, background): “Their models predict that more than 39 million people will have NAFLD, with annual direct medical costs of approximately $62 billion ($1,584 per patient) in the US.”
• Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis (2019, background): “1%.(19) The cumulative incidence of HCC among patients with NAFLD and cirrhosis has been reported to range from 2.”
• The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe (2016, methodology): “In addition to cirrhosis, there is mounting evidence that NAFLD is an important risk factor for HCC.(12,13) Although cirrhosis in NASH has been indicated as a risk factor for HCC, there is some evidence to suggest that NAFLD patients without cirrhosis may also be at risk of developing HCC.(14) Final”
• Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention (2020, background): “Younossi et al.(16) 2004–2009 USA 4,929 patients with HCC identified within the Surveillance, Epidemiology and End Results registry; 701 patients with NAFLD-related HCC ICD-9 codes for NAFLD, cryptogenic liver disease with diabetes or obesity, liver cirrhosis without mention of alcohol or other live”